Contributions
Abstract: P989
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Paediatric MS
Aim: Description of clinical, biological and radiological characteristics of MOG antibodies (Ab) associated pediatric acute demyelinating syndrome (ADS) and their outcome during a follow-up in a large nationwide prospective cohort
Methods: Children (< 18 years old) followed in the French national referral center for rare inflammatory diseases of brain and the spinal cord and tested positive for MOG-Ab by live cell-based assay, were included in this study. Clinical, biological and radiological characteristics as well as outcome were evaluated.
Results: 76 children were included and mean age at onset was 9,5±5,4 years old, and 35 (46%) were girls. At onset, incoercible vomiting (n=1, 1%) and seizures (n=3, 4%) were rarely reported and none of our children had hiccups or pruritis. The most frequent clinical phenotypes at onset were optic neuritis (ON, n=30, 40%) followed by acute disseminated encephalomyelitis (ADEM, n=20, 26%) and transverse myelitis (TM, n=8, 11%). CSF studies showed pleiocytosis in 53%, and oligo-clonal bands in 7% of tested children. Thalamic lesions tend to be more frequent in non relapsing MOG-Abs-ADS than those who are relapsing (n=9 (53%) vs n=6 (23%), p=0,045). Mean follow-up period was 3,8±6,1 years, relapse occurred in 41 (54%) children who experienced between 1 and 10 relapses. At last follow-up, EDSS score was 0,9±1,5 and only 3 children had an EDSS score above 4.
Conclusion: MOG-Abs-ADS is frequently associated to a relapsing course, which could differ radiologically from non relapsing disease. Although, clinical outcome appears favorable longer follow up and cognitive assessments need to be performed.-
Disclosure: Kumaran Deiva is an investigator in trials with Novartis, Sanofi and Biogen and received consultancy fees from Biogen, Novartis, Sanofi.
R. Marignier has received consulting and lecturing fees, travel grants, and research support from Bayer-Schering, Biogen Idec, Genzyme, Novartis, Merck Serono, Roche, SanofiAventis, and Teva Pharma. Go to Neurology.org/N for full disclosures.
A. Cobo-Calvo has received grant from Fundacio ́n Alfonso Martin Escudero.
All other authors have nothing to disclose
Abstract: P989
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Paediatric MS
Aim: Description of clinical, biological and radiological characteristics of MOG antibodies (Ab) associated pediatric acute demyelinating syndrome (ADS) and their outcome during a follow-up in a large nationwide prospective cohort
Methods: Children (< 18 years old) followed in the French national referral center for rare inflammatory diseases of brain and the spinal cord and tested positive for MOG-Ab by live cell-based assay, were included in this study. Clinical, biological and radiological characteristics as well as outcome were evaluated.
Results: 76 children were included and mean age at onset was 9,5±5,4 years old, and 35 (46%) were girls. At onset, incoercible vomiting (n=1, 1%) and seizures (n=3, 4%) were rarely reported and none of our children had hiccups or pruritis. The most frequent clinical phenotypes at onset were optic neuritis (ON, n=30, 40%) followed by acute disseminated encephalomyelitis (ADEM, n=20, 26%) and transverse myelitis (TM, n=8, 11%). CSF studies showed pleiocytosis in 53%, and oligo-clonal bands in 7% of tested children. Thalamic lesions tend to be more frequent in non relapsing MOG-Abs-ADS than those who are relapsing (n=9 (53%) vs n=6 (23%), p=0,045). Mean follow-up period was 3,8±6,1 years, relapse occurred in 41 (54%) children who experienced between 1 and 10 relapses. At last follow-up, EDSS score was 0,9±1,5 and only 3 children had an EDSS score above 4.
Conclusion: MOG-Abs-ADS is frequently associated to a relapsing course, which could differ radiologically from non relapsing disease. Although, clinical outcome appears favorable longer follow up and cognitive assessments need to be performed.-
Disclosure: Kumaran Deiva is an investigator in trials with Novartis, Sanofi and Biogen and received consultancy fees from Biogen, Novartis, Sanofi.
R. Marignier has received consulting and lecturing fees, travel grants, and research support from Bayer-Schering, Biogen Idec, Genzyme, Novartis, Merck Serono, Roche, SanofiAventis, and Teva Pharma. Go to Neurology.org/N for full disclosures.
A. Cobo-Calvo has received grant from Fundacio ́n Alfonso Martin Escudero.
All other authors have nothing to disclose